Država: Kanada
Jezik: angleščina
Source: Health Canada
OMEPRAZOLE
APOTEX INC
A02BC01
OMEPRAZOLE
20MG
CAPSULE (DELAYED RELEASE)
OMEPRAZOLE 20MG
ORAL
100/500
Prescription
PROTON-PUMP INHIBITORS
Active ingredient group (AIG) number: 0121643001; AHFS:
APPROVED
2004-01-27
_APO-OMEPRAZOLE (Omeprazole delayed-release capsules) _ _Page 1 of 49 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR APO-OMEPRAZOLE Omeprazole Delayed-Release Capsules Capsules (delayed release), 20 mg, Oral Apotex Standard Proton Pump Inhibitor APOTEX INC. 150 Signet Drive Toronto, Ontario M9L 1T9 Date of Initial Authorization: January 27, 2004 Date of Revision: August 31, 2023 Submission Control Number: 273446 _APO-OMEPRAZOLE (Omeprazole delayed-release capsules) _ _Page 2 of 49 _ RECENT MAJOR LABEL CHANGES Not applicable. TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................. 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ................................................................................................................ 4 1.1 Pediatrics ............................................................................................................... 4 1.2 Geriatrics ............................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................... 4 4 DOSAGE AND ADMINISTRATION .................................................................................. 4 4.1 Dosing Considerations ........................................................................................... 4 4.2 Recommended Dose and Dosage Adjustment ....................................................... 5 4.4 Administration ....................................................................................................... 7 4.5 Missed Dose .................................... Preberite celoten dokument